
    
      This is a multi-center, evaluator and subject blinded, randomized, vehicle-controlled,
      parallel group, dose-ranging study to be conducted in approximately 150 subjects with acne
      vulgaris. Subjects who satisfy the entry criteria at the Baseline visit will be randomized to
      NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel in a 1:1:1 ratio. Efficacy assessments will
      include inflammatory and non-inflammatory lesion counts and investigator global assessments
      (IGA). Tolerability and safety assessments include cutaneous tolerability evaluation, adverse
      event collection, physical exams, and laboratory studies. Subjects will return for
      post-baseline evaluation at Weeks 2, 4, 8, and 12.
    
  